Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Up – What’s Next?

Capricor Therapeutics, Inc. (NASDAQ:CAPR)’s share price gapped up prior to trading on Wednesday . The stock had previously closed at $26.05, but opened at $27.28. Capricor Therapeutics shares last traded at $27.41, with a volume of 142,259 shares.

Wall Street Analyst Weigh In

CAPR has been the topic of a number of analyst reports. HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of Capricor Therapeutics in a research note on Wednesday, May 13th. B. Riley Financial lifted their price target on Capricor Therapeutics from $50.00 to $63.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Capricor Therapeutics in a research note on Monday. Cantor Fitzgerald set a $62.00 price target on Capricor Therapeutics and gave the stock an “overweight” rating in a research note on Friday, March 13th. Finally, Piper Sandler reissued an “overweight” rating and issued a $58.00 price target (up from $45.00) on shares of Capricor Therapeutics in a research note on Friday, March 13th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Capricor Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $48.36.

Capricor Therapeutics Stock Performance

The company has a 50 day simple moving average of $30.65 and a two-hundred day simple moving average of $27.74. The company has a market cap of $1.60 billion, a PE ratio of -11.89 and a beta of 0.39.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.04). As a group, analysts expect that Capricor Therapeutics, Inc. will post -0.75 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Karimah Es Sabar sold 61,265 shares of the business’s stock in a transaction that occurred on Tuesday, March 31st. The stock was sold at an average price of $30.17, for a total value of $1,848,365.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Anthony Bergmann sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 31st. The stock was sold at an average price of $30.13, for a total value of $753,250.00. Following the sale, the chief financial officer directly owned 8,223 shares of the company’s stock, valued at $247,758.99. The trade was a 75.25% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 172,529 shares of company stock worth $5,302,440. Company insiders own 9.20% of the company’s stock.

Institutional Investors Weigh In On Capricor Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Glenmede Trust Co. NA boosted its position in Capricor Therapeutics by 13.2% during the first quarter. Glenmede Trust Co. NA now owns 36,330 shares of the biotechnology company’s stock worth $1,104,000 after purchasing an additional 4,240 shares during the period. Bank of America Corp DE boosted its position in Capricor Therapeutics by 672.0% during the first quarter. Bank of America Corp DE now owns 415,483 shares of the biotechnology company’s stock worth $12,631,000 after purchasing an additional 361,664 shares during the period. Stempoint Capital LP boosted its position in Capricor Therapeutics by 110.6% during the first quarter. Stempoint Capital LP now owns 37,592 shares of the biotechnology company’s stock worth $1,143,000 after purchasing an additional 19,739 shares during the period. Janus Henderson Group PLC bought a new stake in Capricor Therapeutics during the first quarter worth approximately $687,000. Finally, Ally Bridge Group NY LLC bought a new stake in Capricor Therapeutics during the first quarter worth approximately $3,463,000. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.